oncolytic hsv  (Amgen)

Journal: Vaccines

Article Title: 4-1BBL-Armed Oncolytic Herpes Simplex Virus Exerts Antitumor Effects in Pancreatic Ductal Adenocarcinoma

doi: 10.3390/vaccines12121309

Figure Lengend Snippet: Oncolytic virus combined with PD-1 therapy. ( A ). Regimen of PD-1 antibody combination therapy in the Pan02-HEVM tumor model. (PBS+αPD-1: n = 6, oHSV+αPD-1: n = 7, oHSV-4-1BBL+αPD-1, n = 7). Tumor volumes were measured with a caliper every third day. The tumor growth curves of the average ( B ) and individual mice ( C ) for each group are shown. ( D ) Survival curves of Pan02_HVEM tumor-bearing mice. *** p < 0.001.

Article Snippet: In 2015, talimogene laherparepvec (T-vec; by Amgen, Thousand Oaks, CA, USA) was approved by the FDA for the treatment of advanced melanoma, making it the first and only FDA-approved oncolytic HSV drug to date.

Techniques: Virus

Journal: Cancer Reports

Article Title: Crosstalk Between the Intratumoral Microbiota and the Tumor Microenvironment: New Frontiers in Solid Tumor Progression and Treatment

doi: 10.1002/cnr2.70063

Figure Lengend Snippet: Clinical trials of oncolytic viruses in combination with immunotherapy or chemotherapy drugs.

Article Snippet: NCT05068453 , Study of Oncolytic Virus in Combination With HX‐008 and Radiotherapy in Melanoma Patients With Liver Metastasis , Melanoma stage IV , Drug: Recombinant Oncolytic HSV‐2 Therapeutic Injecta (Vero Cell) for Human Use (rHSV2hGM‐CSF) Drug: Recombinant humanized anti‐PD‐ 1 monoclonal antibody for injection Radiation: RT , Phase 1.

Techniques: Virus, Injection, Recombinant, Inhibition